MEKiAUTO: A phase I/II open-label study of combination therapy with the MEK inhibitor cobimetinib, Immune-checkpoint blockade with atezolizumab, and the AUTOphagy inhibitor hydroxychloroquine in KRAS-mutated advanced malignancies.

Authors

Alexander Raufi

Brown University/Lifespan Cancer Institute, Providence, RI

Alexander Raufi , Winston Wong , Shing Mirn Lee , Gulam Abbas Manji

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Breakthrough

bookmark_border

MEKiAUTO: A multicenter phase 1 study of combination therapy with the MEK inhibitor, cobimetinib, immune checkpoint blockade, atezolizumab, and the autophagy inhibitor hydroxychloroquine (HCQ) in KRAS-mutated advanced malignancies.

First Author: Gulam Abbas Manji

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRAS^G12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring KRAS p.G12C mutation (CodeBreak 101).

First Author: Marwan Fakih

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

An open-label clinical trial of RP2 and RP3 oncolytic immunotherapy in combination with atezolizumab and bevacizumab for the treatment of patients with advanced colorectal carcinoma.

First Author: Dale Randall Shepard

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC).

First Author: Johanna C. Bendell